Share
A top podcast for healthcare leaders, with over one million downloads, Radio Advisory is your weekly download on how to untangle the industry's most pressing challenges to help leaders like you make the best business decisions for your organization. From unpacking major trends in care delivery—like site-of-care shifts and the rise of high-cost drugs—to demystifying stakeholder dynamics, to shining a spotlight on priorities that may get overlooked, we're here to help. Our hosts and seasoned r ...
…
continue reading
Manage episode 519871534 series 2739469
Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
We love to hear from our listeners. Send us a message.
Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides lower interest rates might bring generalist investors back into the sector.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Setting The Stakes For Biotech (00:00:00)
2. Big-Deal MA And Ecosystem Effects (00:01:29)
3. IPO Backlog And What Unlocks It (00:03:50)
4. Crossovers, Mutual Funds, And Allocation (00:06:20)
5. Avoiding Broken Issues And Rate Dynamics (00:09:10)
6. Buyout Versus IPO: Value And Returns (00:12:00)
7. Post-IPO Value: Liquidity And Currency (00:15:20)
8. Managing Expectations And Milestones (00:18:10)
9. Timing Catalysts Around An IPO (00:21:10)
10. Generalists Returning And What It Takes (00:24:00)
11. Hot Modalities: ADCs And Radiopharma (00:27:00)
12. Staying Relevant With Catalyst Cadence (00:29:10)
13. Collaborate Strategically, Not As A CRO (00:31:30)
14. Collaboration Tradeoffs And Opportunity Cost (00:34:00)
15. Building A Partnership Pipeline (00:37:00)
16. Alternative Financing And Spending Discipline (00:40:00)
17. Prioritising Programs For Impact (00:43:10)
18. Key Risks: FDA, Capital, And China (00:46:00)
19. Global Speed Advantage And Offshore Trials (00:49:30)
20. Closing Thoughts And Where To Subscribe (00:53:10)
281 episodes
))
